ValoreQ4, 24Q4, 25TTMSpese di vendita, generali e amministrative———Ricerca e sviluppo———Reddito operativo———Proventi non operativi, Totale———Oneri finanziari, al netto degli interessi capitalizzati———Proventi non operativi, esclusi gli oneri finanziari———Entrate/uscite straordinarie———Utile al lordo delle imposte———Quota di utile———Imposte———Interessi di minoranza———Altri proventi/oneri al netto delle imposte———Utile netto al lordo delle attività cessate———Attività cessate———Utile netto———Regolazione della diluizione———Dividendi privilegiati———Utile netto diluito attribuibile agli azionisti ordinari———Utile base per azione (EPS base)———Utile diluito per azione (EPS diluito)———Numero medio di azioni ordinarie in circolazione———Azioni diluite in circolazione———EBITDA———EBIT———Costo del fatturato———Altri costi del venduto———Ammortamento e svalutazione (liquidità)———
Fresenius Medical Care AG American Depositary Shares (Each repr
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease, which requires patients to undergo dialysis 3 times per week for the rest of their lives.
With a global headquarters in Bad Homburg vor der Höhe, Germany, and a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States. It also operates 42 production sites, the largest of which are in the U.S., Germany, and Japan.
The company is 32% owned by Fresenius and, as of 2020, generates around 50% of the group's revenue.
As of 2024, the company was ranked as #612 on the World's Best Employers list published by Forbes.